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Poor outcome for breast cancer in Ghana have been attributed to late presentation of symptoms 36 
at biomedical facilities. This study explored factors accounting for delays in initiation of breast 37 
cancer treatment at the Korle-Bu Teaching Hospital in Accra. Focus group discussions were 38 
conducted with twenty women with breast cancer. A theory-driven thematic analysis identified 39 
three multilevel factors influencing treatment seeking delays: (1) patient (e.g misinterpretation of 40 
symptoms, fear); (2) healthcare provider (e.g negative attitudes); and (3) health systems (e.g 41 
shortage of medicines). Addressing treatment delays will require multilevel interventions, 42 
including culturally congruent education, psychosocial counselling/support, and strengthening 43 
health systems. 44 
 45 
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Research has shown high morbidity and mortality of breast cancer in Ghana (Atobrah, 2013; 61 
Wiredu and Armah, 2006). Even though early breast cancer diagnosis and treatment at a pre-62 
symptomatic phase are associated with prolonged survival, the majority of breast cancer patients 63 
in Ghana present late (Bish et al., 2005; Richards et al., 1999) with 52-85% presenting with 64 
advanced disease (Clegg-Lamptey and Hodasi, 2007; Ohene-Yeboah and Adjei, 2012).  65 
Studies have shown that longer delays to the start of breast cancer treatment are associated with 66 
worse survival rates (Richards et al., 1999; Ohene-Yeboah and Adjei, 2012). Total delay has 67 
been defined as the time between a patient’s discovery of symptoms and start of definitive 68 
treatment in a health facility: total delay is a product of patient and provider/treatment delay. 69 
Treatment delay can be attributed to both patient factors and health systems factors. Similar to 70 
other chronic non-communicable diseases (NCDs), such as diabetes and hypertension, there are 71 
many barriers to timely treatment of breast cancer.  72 
Several studies have been conducted on various aspects of breast cancer in Ghana, including 73 
patient delay that explores the causes of delay in seeking initial treatment (Atobrah, 2013). But 74 
there is presently no study which examines patients’ perspectives on treatment delay looking at 75 
the causes of delay in start of treatment between first presentation at the hospital for diagnosis 76 
with breast cancer and the start of definitive treatment. As part of a large-scale hospital-based 77 
study of patients who have started treatment for breast cancer at the Korle Bu Teaching Hospital 78 
(KBTH), Accra, this study explores the patients’, healthcare providers’ and health systems’ 79 
factors which accounted for delay in start of definitive treatment, using a qualitative approach. In 80 
this study, delay was defined as the time interval (and factors responsible for that interval) 81 





Data was gathered using Focus Group Discussions (FGDs) to examine the structure, process and 85 
outcomes of social communication in order to gain insight into “how knowledge, and more 86 
importantly ideas, develop and operate within a given cultural context” (Kitzinger, 1995). Four 87 
FGDs were carried out with patients receiving treatment from the general surgical wards and 88 
outpatient clinics of the department of surgery, and the breast clinic of the National Center for 89 
Radiotherapy and Nuclear Medicine, KBTH.   90 
Participants 91 
Participants were recruited using purposive sampling from the general surgical wards, outpatient 92 
clinics, and the breast clinic of the National Center for Radiotherapy and Nuclear Medicine at 93 
KBTH.  The fieldwork was carried out between August and September, 2013. The first phase of 94 
the fieldwork was a survey where 205 consecutive breast cancer patients starting treatment at the 95 
study sites were recruited (Dedey et al., 2016). After the end of the survey, we followed up some 96 
of the patients by calling them on their mobile phones to request their participation in a focus 97 
group discussion to gather more nuances and in-depth information on the causes of delay in start 98 
of definitive treatment. We were able to approach thirty-one patients at this stage and eleven of 99 
them declined. Once participants had agreed, we set up their interview dates and they were 100 
placed in groups based on their clinic days. The FGDs were conducted in English and Twi by 101 
trained field assistants. The duration of the group discussions ranged from an hour thirty minutes 102 
to two hours thirty minutes and permission was sought from the participants to record all 103 
discussions.   Ethical approval for the study was obtained from the Ethical and Protocol Review 104 
Committee of University of Ghana Medical School. 105 
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Further, all participants were remunerated for participating in the study. Each participant was 106 
given GH20 (US$9.67) as transport allowance. Two pre-defined key areas were explored in this 107 
study: 1) general life history; and; 2) patients, healthcare providers’ and health systems’ causes 108 
of delay in start of breast cancer treatment. Questions asked during the FGDs are provided in 109 
Supplementary Box 1. The profiles of the breast cancer patients are presented in Table 1 and 110 
Supplementary Table 1b. 111 
Data analysis 112 
The data analysis was conducted after all the interviews were transcribed. All interviews were 113 
transcribed verbatim from Twi into English language by a team of transcribers with Twi and 114 
English language competence. We analysed the data using thematic approach (Attride-Stirling, 115 
2001). The analysis was guided by a coding frame with two sections; 1) a section on pre-existing 116 
deductive codes derived from previous studies on causes of delay in breast cancer treatment, and; 117 
2) an open-ended section of inductive codes derived from the lived experience of the 118 
participants. 119 
The study by Freitas and Weller (2015) on ‘patient delays and systems delays in breast cancer 120 
treatment in developed and developing countries’ and the review of breast cancer research in 121 
Ghana by Atobrah (2013) guided the selection of the deductive codes.  Deductive codes derived 122 
from the reference studies included financial constraints, non-attribution of symptoms to cancer, 123 
fear of: disease, treatment adverse effect and chemotherapy. Deductive codes for healthcare 124 
provider and health systems factors were derived from key elements of  the WHO health systems 125 
building blocks (service delivery, health workforce, information system, medicines, financing 126 
and leadership/governance)  (Coast et al., 2016) and the application of this framework to cancer 127 
care in Africa (Adeloye and Grant, 2016). Using the principle of constant comparison, the 128 
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emerging themes were compared against each other to describe the depth and coverage of themes 129 
across transcripts. We paid critical attention to consensus, conflict and absences across group and 130 
individual narratives (de-Graft Aikins, 2005).  131 
The second stage of the analytical framework involved drawing  linkages between codes, 132 
themes, appropriate respondent quotes, existing empirical studies and  conceptual ideas from 133 
social representations theory (de-Graft Aikins, 2005) and explanatory models of illness 134 
(Kleinman, 1980). The concepts of social representation and explanatory models shaped the 135 
interpretive analysis because we were interested in the sources of knowledge and how sources 136 
influenced practical responses on treatment. At the interpretive stage, we re-categorised some of 137 
the themes mentioned by participants, partly informed by convergent and divergent themes from 138 
existing studies. For instance, participants reported different dimensions of fear; we highlighted 139 
the different levels through which fear operated so that we could identify the extent to which this 140 
theme aligned with existing studies that had reported fear as a barrier to start of definitive 141 
treatment.  142 
Results 143 
The results focus on causes of delay in breast cancer treatment.  144 
Causes of delay in breast cancer treatment 145 
Causes of delay in breast cancer treatment are presented under three broad categories: (1) patient 146 
factors (2) healthcare provider factors, and; (3) health system factors. All the categories were 147 
examined from the patients’ perspectives. 148 
Patient factors 149 
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The participants attributed their causes of delay in start of definitive treatment to four main 150 
themes: i) spiritual causal theories of breast cancer; ii) fear; iii) financial constraints, and; iv) 151 
seeking alternative treatment. 152 
Spiritual causal theories of breast cancer  153 
A major cause of delay in start of definitive treatment was spiritual causal theories of breast 154 
cancer. Participants attributed the causes of breast cancer to spiritual causes such as witchcraft, 155 
breast-feeding in dreams and consequence of one’s sin. These theories influenced their decision 156 
to seek spiritual help before starting biomedical treatment.   157 
Up until now, I think it is a satanic disease because before it happened, I was at a 158 
Christian gathering where the Pastor said that if you have a dream and a child is sucking 159 
your breast it means you are being given breast cancer. At the time, I listened but I did 160 
not believe it completely. I used to have such dreams a lot (FGD 4-R1). 161 
I thought I was being bewitched; in my case I had no dream but by all indication I know I 162 
had been bewitched by family members. Because immediately after my engagement, my 163 
mother said one of my aunties kept asking if I had become pregnant (FGD 1-R2). 164 
Fear 165 
Fear was another dominant cause of delay in start of treatment; this was mentioned and discussed 166 
by all the participants. The different targets of fear mentioned by the participants included fear 167 
of: mastectomy, breast damage, surgery, perceived trauma from the treatment and Korle Bu 168 
Teaching Hospital.  169 
…there was indeed that fear but when I was admitted here, I realized that there was 170 
nothing to be afraid of. But what really scared me was the surgery; okay, so when you 171 
had to come to Korle-bu you cried, and when you had to come for surgery too you cried 172 
again (FGD 1-R5). 173 
 174 
I’m always afraid of things….when you are admitted at Korle-bu, it’s like you’re as good 175 
as dead; I’m scared of everything about Korle-bu. When I had to come here, I cried a 176 
lot… (FGD 1-R2) 177 
8 
 
…..the first time I was scared because I don’t normally come to Korle-bu. They only deal 178 
with serious issues so then … it was serious if you were sent there. So you see that 179 
anytime I am coming, then my B.P goes up, because I didn’t know what to expect next 180 
(FGD 3-R1). 181 
Fear was also driven by the perceptions of women’s significant others. There was a common 182 
perception that mastectomy damaged ‘female identity’ or ‘ideal womanhood’. Women were 183 
advised against the procedure, as a result. These perceptions intensified the fear women felt 184 
about cancer and prevented them from seeking definitive treatment.  185 
…some noted that as a woman, if your breast is removed then it is your sure ticket to 186 
death…. these are some of the things people say to dissuade others from seeking early 187 
medical attention….(FGD 1-R3) 188 
some people told my husband that I should not undergo the surgery… he said that if I 189 
undergo the surgery I would die in a year’s time (FGD 1-R2) 190 
Financial Constraints 191 
Many of the patients mentioned lack of finances as a major barrier to start of definitive 192 
treatment. This is another major theme which emerged from the narratives of all the participants 193 
and this cut across different educational and socio-economic status. Most participants struggled 194 
to pay the high cost of chemotherapy, pharmaceutical drugs and other associated costs of breast 195 
cancer treatment.  196 
The chemo is expensive. The trauma and money you spend too is a problem. If you do not 197 
have at least 200 Ghana cedis, you cannot buy the drugs. When someone hears all these, 198 
the individual would opt for herbal medicine or prayer. So as for me I think that lack of 199 
money is a factor. I paid 1000 Ghana cedis to use the chemo machine. If you do not have 200 
money you would go home. So money is a serious factor (FGD 4-R1). 201 
 202 
Alternative treatment 203 
Participants also attributed their delay in start of definitive treatment to seeking alternative 204 
treatments such as herbal treatment, faith healing and practice of lifestyle modification treatment 205 
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after confirmation of diagnosis. Based on the narratives of some of the participants, seeking 206 
alternative treatment was not only driven by faith in alternative treatment, but by the high cost of 207 
biomedical treatment.  208 
……there was a little sore on my breast and my breast swelled up and we took it to the 209 
hospital and I was diagnosed with breast cancer. We tried treating it there but the 210 
amount we were charged was too much and we could not afford and we stopped the 211 
treatment at the hospital and we started using herbal medicine. The situation worsened 212 
and the whole breast became sore and we then decided to come to Korle-Bu (FGD 2-R3) 213 
Further, the participants’ narratives indicate that religious leaders contributed to delay in start of 214 
definitive treatment. Some participants were associated with pastors who encouraged them to use 215 
faith healing instead of seeking biomedical treatment. 216 
…the pastors contribute to the delay in response time to treatment medically. They tell 217 
people that they can pray for the disease to melt away. Your faith also tells you that they 218 
can do it so after the prayers, you sit back knowing and believing that you are healed, but 219 
that might not exactly be the news (FGD 1-R4). 220 
 221 
…I did not tell anyone, except my husband and the people I pray with. I always say my 222 
faith is that God can cure me…. this is what is happening so pray with me… There is this 223 
pastor friend who said Ok, some went through chemo and also, other people used herbal 224 
medicine and are fine, he also said he knew others too that used bio-med and are also 225 
fine, therefore if it is my faith that prayer can heal me I can go ahead and pray (FGD 2-226 
R2). 227 
Participants also sought alternative treatment because they believed in it and because the health 228 
workers advised them to do so. The narratives of the participants suggested that aggressive 229 
campaigning by the herbal industry was driving engagement with alternative herbal treatments 230 
…some prefer herbal medicine because there is a lot of noise being made about these 231 
herbal centres (FGD 1-R1). 232 
           233 
 …there are nurses who even tell you that they know a herbalist who can put some cream 234 
there and it will melt. They ask you whether you want your breast to be lacerated (FGD 235 
3-R3). 236 
Health care provider factors 237 
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Participants mentioned that healthcare providers also contributed to the delay in start of 238 
definitive treatment. The healthcare provider factors which accounted for delay in start of 239 
definitive treatment included: i) the healthcare workers’ attitude; ii) corruption among the 240 
healthcare workers, and; iii) wrong/harmful advice from healthcare workers. The dominant 241 
healthcare provider factor mentioned and discussed by the majority of the participants was poor 242 
attitude of the health workers.  Patients stated that some of the healthcare workers were rude to 243 
them or refused to answer their questions and did not treat them well and this forced them to 244 
delay start of treatment or stopped treatment for some time. In addition, participants mentioned 245 
that some of the health workers are corrupt because they give preferential treatment to patients 246 
that they know.  247 
The record staff are not too nice. There is one particular lady who calls the name and 248 
expects you to hurry from wherever you are to come for your own card. You see some of 249 
us are very sick and others very old so it will take time but when a little time elapse after 250 
she has called your name and you get there, she shouts on you and all that and is not 251 
nice. So for the medical staff there is no problem with them but for the record staff they 252 
are not nice. You would even like to ask them a question but they will not be bothered 253 
(FGD 3-R3).  254 
…I would say that for the lab, they keep to their time and date. When you go, the results 255 
would be ready but you would have to wait a while. The problem with the lab attendants 256 
who are to bring the reports out would be sitting behind their computers and be chatting. 257 
We the patients would have to queue up. When names are mentioned, the attendants do 258 
not speak audibly. When you ask a question, they would shout at you and ask you if you 259 
did not hear them as they were calling out the name. At certain times, waiting to receive 260 
the lab report is a matter of who you know. Someone who has not joined the queue would 261 
just walk in and be served immediately because the person knows someone who works in 262 
the lab. If you don’t know anybody working in the lab you would have to queue (FGD 4-263 
R2). 264 
Further, participants said that health care workers give wrong/harmful advice to patients by 265 
encouraging them to seek alternative treatment, and this eventually causes delay in start of 266 
definitive treatment.  267 
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…there are nurses who even tell you that they know an herbalist who can put some 268 
cream there and it will melt. They ask you whether you want your breast to be lacerated 269 
(FGD 3-R3). 270 
Health Systems factors 271 
The health systems factors that led to delay in treatment, as narrated by the participants, include: 272 
i) long queues during treatment; ii) unavailability of doctors; iii) breakdown of hospital 273 
machines; iv) shortage of medicines; v) workload of doctors; vi) shortage of health care workers; 274 
vii) slow moving queues at the drug dispensary, and; viii) long distance between departments 275 
involved in breast cancer treatment within the hospital premises. Some of the participants 276 
mentioned that the structure of breast cancer treatment at KBTH contributed to the delay. 277 
Treatment facilities were located at different places within the hospital premises and this made it 278 
strenuous for patients to access these facilities. The dominant theme for the health system’s 279 
delay, mentioned and discussed by many of the participants was delay of biopsy results from the 280 
Pathology department.  281 
I think I agree with them, doing lab here and there makes the whole process very tiring so 282 
if we get everything here, we will be happy. Because sometimes, after the whole thing, 283 
you seem to be overused and stressed and I always feel dizzy. If cancer patient would 284 
have a sort of special treatment (FGD 3-R1). 285 
yes. After my first surgery the red house (Pathology Unit) delayed my lab results too 286 
much. It made me restless and worried because I didn’t know whether I was making 287 
progress or not; Whenever you go to the lab, it will takes months before you get the 288 
results. So if it is because the machines are not much or it’s because the equipment is 289 
inadequate, I can’t tell. The difference between this one and the one from South Africa is 290 
that, the one from South Africa comes early whiles this one does not (FGD 3-R1). 291 
 292 
 293 
Recommendations on how to reduce delay in start of treatment 294 
The recommendations on how to reduce delay in start of treatment at KBTH are based on the 295 
narratives of the participants. The participants were asked to suggest ways to reduce delay in 296 
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start of breast cancer treatment. The narratives of the participants were thematised based on the 297 
WHO health systems building blocks and these focused on: 1) health service delivery; 2) health 298 
workforce, and; 3) financing. We present these themes in Table 2, highlighting the spread of 299 
views across groups. 300 
<INSERT HERE> 301 
DISCUSSION 302 
This discussion focuses on the three factors driving delay in start of breast cancer treatment: 303 
patients, health professionals and health systems. 304 
Patient factors 305 
The dominant patient factor for causes of delay in start of breast cancer treatment among the 306 
participants was fear. Fear has also been identified in several studies as one of the most dominant 307 
causes of delay in start of breast cancer treatment in high income countries and LMICs (Freitas 308 
and Weller, 2015; Crowley et al., 2014; Innos et al., 2013).  Fear operated at multiple levels of 309 
analysis: the level of self (changed body), at the level of intimate and socially significant 310 
relationships (changed identity as a woman), at the level of macro-structure (fear of Korle-Bu 311 
Teaching Hospital), and at the level of the supernatural (fear of the spiritual causes of cancer). 312 
There is a need to identify the multi-faceted (subjective, material and symbolic) targets of 313 
women’s fear in order to develop appropriate psychosocial counselling and support. 314 
Another major cause of participants’ delay in start of treatment was financial constraints. 315 
Financial constraints as a cause of patient delay have also been cited in other studies (Atobrah, 316 
2013; Dedey et al., 2016; Barros et al., 2013; Ermiah et al., 2012; Quaife et al., 2014; Sharma et 317 
al., 2013). High cost of biomedical treatment forced some of the participants to seek alternative 318 
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sources of healing which resulted in delay in start of treatment. The economic downturn in 319 
Ghana, coupled with high cost of living, make it difficult for most families to meet their day to 320 
day needs; chronic illnesses such as breast cancer often introduce catastrophic healthcare 321 
expenditures within this context  (de-Graft Aikins et al., 2014; Tagoe, 2012). Participants 322 
struggled to pay their cancer care costs.   Those who had health insurance, still had to pay out-of-323 
pocket at the point of healthcare delivery because many of the breast cancer treatments were not 324 
covered by the National Health Insurance Scheme (NHIS). Experts observe that NCDs send 325 
patients and their families down a poverty spiral, particularly in LMICs where 60% of healthcare 326 
is financed out-of-pocket, compared to 20% out-of-pocket expenses in high income countries 327 
(Quaife et al., 2014; Richards et al., 1999; Coast et al., 2016). Local experts have advocated the 328 
need for a non-communicable disease (NCD)-competent NHIS – a restructured system with an 329 
expanded remit  to cover the comprehensive treatment needs of a growing number of Ghanaians 330 
living with cancers and other chronic conditions (de-Graft Aikins and Koram, 2017). This will 331 
reduce the financial burden of care on individuals and families, as well as the associated 332 
psychosocial burdens.   333 
Some of the participants in this study thought that breast cancer has spiritual causes. As a result, 334 
some of them sought alternative treatment which ended up delaying the time they started 335 
definitive treatment at KBTH. Some studies have also reported seeking of alternative treatment 336 
as a cause of delay in start of treatment (Freitas and Weller, 2015).Other reasons given by 337 
participants for delay in start of treatment were spousal and family restrictions. Socio-cultural 338 
systems, as well as theories of disease and illness, especially in African settings, have been 339 
known to influence decision for seeking medical treatment especially in females (BeLue et al., 340 
2009). It has been reported that major decisions on women’s health and wellbeing are usually 341 
14 
 
taken by the husband or family member who determines if it is appropriate to seek medical help 342 
based on their own beliefs, knowledge of the disease and financial status (Ohasi et al., 2014). 343 
The narratives of the participants in this study suggest that some of the women delayed start of 344 
definitive treatment due to the advice given by their significant others (e.g husbands, sisters, and 345 
other valued family members).   346 
Health care providers’ and health systems’ factors  347 
The healthcare provider and health systems delay were examined through the WHO health 348 
systems building blocks framework. With regard to service delivery, this study showed that 349 
many of the patients did not have access to quality treatment due to the poor attitudes and corrupt 350 
practices of the healthcare workers. Associations have been made between Ghana’s weak health 351 
system and recurring trends in corrupt health worker practices (de-Graft Aikins and Koram, 352 
2017). Corrupt practices entrenched inequitable access to breast cancer treatment at KBTH. 353 
Some of the participants were able to utilize the healthcare service faster than others because 354 
they attracted the favour of the healthcare workers either through bribery or leveraging their 355 
personal relationships with the healthcare workers. Other factors that hindered quality health 356 
service delivery included location of treatment facilities at different places within the hospital 357 
premises and long queues during treatment.  358 
With respect to the health workforce, the participants mentioned shortage of healthcare workers 359 
as an impediment to receiving quality treatment. The numbers of breast cancer specialists at 360 
KBTH are too few to handle the influx of breast cancer patients and this contributed to delay in 361 
start of treatment. An effective way of addressing this may be using a task-shifting approach to 362 
train physicians in breast cancer care so as to increase the number of health professionals that can 363 
deliver this care (Adeloye and Grant, 2016).  364 
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With respect to medical products and technology, the participants mentioned delay in biopsy 365 
results from Pathology Unit as a dominant cause of health systems delay in start of treatment. 366 
This factor had been reported to be a major determinant of delay in start of definitive treatment at 367 
KBTH (Dedey et al., 2016). In addition, intermittent breakdown of machines at the hospital due 368 
to power fluctuations and occasional delays in dispensing chemotherapy drugs are issues that are 369 
of concern to the country as a whole. With improvement in electricity supply to KBTH, 370 
subsidization of cost of chemotherapy drugs and tax exemption on drugs, the above problems 371 
may be minimised (Vanderpuye and Yarney, 2014). 372 
With respect to recommendations on how to reduce delay in breast cancer treatment, the 373 
suggestions of the participants focused broadly on health service delivery, health workforce, and 374 
financing. The other components of the health system – information and leadership/governance – 375 
emerged as implicit concerns. For example, the lack of cancer education was implicated in low 376 
levels of awareness and understanding of breast cancer systems. This may be a product of poor 377 
investment in health information systems. The chronic problem with the operation of the 378 
Pathology Unit may also be a product of poor leadership and governance at the hospital.   379 
The main limitation of this study was that the number of participants included in the FGDs was 380 
very limited.  We could not gain access to many of the participants that were interviewed during 381 
the survey phase. Even though we were able to approach thirty-one participants in total, we 382 
could not obtain permission from some of them. Despite this limitation, meaning saturation was 383 
reached on the majority of the discussion themes. As a result, the nuanced patients’, health care 384 
providers’ and health systems’ factors generated on patients’ perspectives on causes of delay in 385 
start breast cancer treatment can inform larger-scale qualitative and quantitative studies in similar 386 
contexts.  387 
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 Conclusion 388 
This study showed that there were different causes and modalities of delay in start of definitive 389 
treatment for breast cancer and this included patients’, healthcare workers’ and health systems’ 390 
factors.  Reducing delays in breast cancer treatment at KBTH will require multi-level 391 
interventions which target these tripartite factors. Such interventions should include: public 392 
education (and education of health workers) on causes and symptoms of breast cancer, including 393 
messages that deconstruct  harmful cultural beliefs; psychosocial counselling before and during 394 
definitive treatment, and; health systems strengthening in the areas of health service delivery 395 
(localisation of breast cancer treatment units at KBTH), health workforce (improving health 396 
professionals’ attitudes, ethical conduct, welfare and diagnostic and treatment timelines) and 397 
financing (advocating for an NCD-competent NHIS).  398 
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Table 1. Socio-demographic details of respondents 505 
Characteristics FGD 1 (n=5) FGD 2 (n=5) FGD 3 (n=4) FGD 4 (n=6) 
Total 
(N=20) 
Age           
 < 40 0 1 0 1 2 
40-49 4 2 1 1 8 
50-59 1 1 2 2 6 
60+ 0 1 1 2 4 
Level of education           
No education 0 1 0 1 2 
Primary 2 0 0 0 2 
Middle/JHS 2 2 0 0 4 
Secondary/JHS 1 1 1 1 4 
Tertiary 0 1 3 0 4 
Missing 0 0 0 4 4 
Marital status           
Currently Married 5 4 2 5 16 
Widowed 0 0 2 0 2 
Separated 0 1 0 1 2 
Religion           
Christianity 5 5 4 0 14 
None 0 0 0 1 1 
Number of children           
0 0 1 0 2 3 
 1-2 1 1 3 1 6 
 3-4 2 2 1 0 5 
5+ 1 1 0 1 3 
Missing 1 0 0 0 1 
Occupation           
Unemployed 0 1 1 0 2 
Trader 5 2 0 3 11 
Others 0 2 3 2 7 
Ethnicity           
Akan 2 1 3 3 9 
Ewe 3 0 0 2 5 
Ga 0 3 0 1 4 
Others 0 1 1 0 2 
Median time (in 
weeks) from 
presentation to start 
of treatment 
    
 
 < 4 0 1 1 2 4 
 4-12 4 1 2 2 9 
 12+ 1 2 1 2 6 
21 
 
Missing 0 1 0 0 1 
Disease Stage           
I & II 5 5 3 0 13 



















































1. Please can you tell us a little bit about yourself? 
2. In your opinion, what are some of the factors that make patients who are diagnosed 
with breast cancer delay in receiving treatment?  
(Probes: socioeconomic status; use of Complementary and Alternative Medicine; 
patient perception; fear of doctors; fear of coming to Korle Bu; travel time/distance 
to Korle Bu) 
3. How do health providers contribute to the delay in the onset of breast cancer 
treatment? 
(Probes: workload; number of patients and documentation; attitude of staff; 
expertise; logistics) 
4. How does the healthcare system in Korle Bu contribute to the delay in breast cancer 
treatment? 
(Probes: availability of adequate numbers of healthcare workers; availability of 
facilities and drugs; time for laboratory investigations and waiting lists)  
5. In your opinion, how can we reduce the waiting time between breast cancer 














Religion Education Ethnicity 





1  41  - Trader Married Christian  Primary  Ewe  5 2 
2  45 5  Trader  Married  Christian  Primary  Akan  29  1  
3  56 4  Trader Married Christian   JHS  Ewe  7 2  
4  49 3  Trader  Married  Christian  SHS   Akan 5  2  










Religion Education Ethnicity 





1 33 2 Hairdresser Married Christian JHS Ga 13 2 
2 48 0 Journalist Married Christian Tertiary Bimoba 6 1 
3 64 4 Retired Married Christian SHS Akan  - 2 
4 45 3 Trader Married Christian JHS Ga 3 2 










Religion Education Ethnicity 










widowed Christian SHS Fante 5 3 
2 51 2 Nurse married Christian Tertiary Kudaasi 6 2 
3 40 2 
Working at 
National 














Religion Education Ethnicity 





1 62 9 Sells cassava Separated none none Ga 52 4 
2 51 4 Teacher Married Christian SHS Akan 5 4 
3 39 2 Trader Married Christian - Ga 3 4 
4 48 0 Trader Married Christian - Ewe 6 4 
5 64 0 Seamstress Married Christian - Akan 3 4 





Table 2 Recommendations on how to reduce delay in start of breast cancer treatment 
  Recommendations Spread of views 
1 Health service delivery  
(1) Spreading breast cancer patients across different days of the week for 
maximum attention to be given to each patient. 
 
(2) Concentration of breast cancer treatment at KBTH in one building so 
as to streamline the processes involved in diagnosis and relieve the 
frustrations patients go through in the hospital. 
 
(3) Public education on causes and symptoms of breast cancer so as to 
facilitate early presentation and treatment. 
Some members 
(FGDs 1, 2 and 3) 
2 Health workforce  
(1) Appropriate follow-up of patients by health professionals to monitor 
their welfare. 
 
(2) Appropriate intervention (such as increasing the number of health 
workers) at the Pathology Unit to reduce delay in getting biopsy results. 
 
(3) Explanation of breast cancer treatment procedures to patients for 
them to make informed decision on the most appropriate treatment. 
 
(4) Motivation of health workers through commission so as to reduce 
corruption and encourage them to provide quality health service to 
patients.  
Some members (All 
groups) 
3 Financing 
(1) Assistance from government through subsidy on cost of treatment FGDs 1 and 4 
 
 
